Assessing placental membrane treatment efficiency in diabetic foot ulcers: Processing for retention versus lamination

Abstract

BackgroundDiabetic foot ulcers are a severe complication in diabetic patients, significantly impact healthcare systems and patient quality of life, often leading to hospitalization and amputation. Traditional Standard of Care (SOC) treatments are inadequate for many patients, necessitating advanced wound care products (AWCPs) like human placental membranes. This study conducts a retrospective analysis to compare the effectiveness of two human placental membrane products, retention‐processed amnion chorion (RE‐AC) and lamination‐processed amnion chorion (L‐AC) in managing chronic diabetic foot ulcers (DFUs).MethodsThe study collected retrospective observational data from electronic health records (EHRs) of patients treated for DFU at three outpatient wound care centers. Patients were categorized into two cohorts based on the treatment received. Key metrics included wound size progression and the number of product applications. The analysis employed Bayesian estimation, utilizing an analysis of covariance model with a Hurdle Gamma likelihood.ResultsWe found that RE‐AC achieved a marginally higher expected Percent Area Reduction (xPAR) in DFUs compared to L‐AC at 12 weeks (67.3% vs. 52.6%). RE‐AC also required fewer applications, suggesting greater efficiency in general wound closure. Probability of full wound closure was similar in both groups (0.738 vs 0.740 in RE‐AC and L‐AC, respectively).ConclusionThe findings suggest that while L‐AC might be slightly more effective in complete ulcer healing, RE‐AC offers overall better treatment efficiency, especially in reducing the frequency of applications. This efficiency can lead to improved patient comfort, reduced treatment costs, and optimized resource utilization in healthcare settings.